Senores Pharmaceuticals Ltd (SENORES) — shareholding pattern, promoter holding, financials and share price
About Senores Pharmaceuticals Ltd (SENORES)
Senores Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SENORES and on the BSE under scrip code 544319. Its ISIN is INE0RB801010.
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities [1]
Senores Pharmaceuticals Limited primarily engages in developing and manufacturing pharmaceuticals for regulated markets such as the US and Canada, along with emerging markets. It has built a robust regimen of ANDAs, facilitating entry in niche, high-complexity therapeutic areas.
Significantly increased its portfolio to 46 approved ANDAs covering 137 strengths, reflecting a scaling up of operations and strategic market penetration. Expected launches from pending ANDAs promise further growth.
Listed peers in Pharmaceuticals: Jeena Sikho Lifecare Ltd, FDC Ltd, Supriya Lifescience Ltd, Aarti Pharmalabs Ltd, Innova Captab Ltd, Bliss GVS Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,415.95 a share on 10 Jul 2026, Senores Pharmaceuticals Ltd (SENORES) was valued at a price-to-earnings ratio of 53.65x against an industry P/E of 36.41x and a price-to-book of 8.29x on a book value of ₹170.71 per share as of Mar 2025. Solomo computes return on equity of 15.46% and return on capital employed of 16.73% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 53.65x
- Industry P/E
- 36.41x
- P/B
- 8.29x
- EPS (TTM)
- ₹26.39
- Book value / share
- ₹170.71
- ROE
- 15.46%
- ROCE
- 16.73%
- ROA
- 9.91%
- Debt / equity
- 0.4x
- Dividend yield
- 0%
- EBITDA margin
- 34.2%
- 52-week range
- ₹586.35 – ₹1,486.7
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Senores Pharmaceuticals Ltd (SENORES) reported revenue of ₹633 crore, net profit of ₹122 crore and earnings per share of ₹25.05. That compares with revenue of ₹398 crore and net profit of ₹58 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹175 crore and net profit ₹37 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 14 | 35 | 215 | 398 | 633 |
| Net profit (₹ cr) | 1 | 8 | 33 | 58 | 122 |
| EPS (₹) | 1.01 | 8.59 | 10.31 | 12.72 | 25.05 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 41.70% | 85.65% |
| Profit growth | 75.57% | 78.36% |
| Stock price CAGR | - | 136% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 45.82% of Senores Pharmaceuticals Ltd (SENORES) (unchanged from the previous quarter), foreign institutional investors (FII) hold 6.62% and domestic institutional investors (DII) hold 9.77%. Promoters have pledged 2.8% of their holding. Market capitalisation was ₹6,521 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2024.
Largest disclosed public shareholders in Jun 2026: Hsbc Mutual Fund - Hsbc Small Cap Fund 3.44%, Astorne Capital Vcc - Arven 1.95%, Manoj Prakash Sanghvi 1.86%, Ratnamani Marketing Private Limited 1.82%, Aditya Birla Sun Life Insurance Company Limited 1.62%, Jayanti Mishrimal Sanghvi . 1.23%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 45.82% | 2.8% | 6.62% | 9.77% | 54.18% |
| Mar 2026 | 45.82% | 1.9% | 3.64% | 9.61% | 54.18% |
| Dec 2025 | 45.8% | 1.9% | 3.35% | 9.31% | 54.2% |
| Sep 2025 | 45.8% | - | 4.28% | 8.61% | 54.2% |
| Jun 2025 | 45.78% | - | 3.67% | 9.51% | 54.22% |
| Mar 2025 | 45.77% | - | 4.17% | 9.65% | 54.23% |
| Dec 2024 | 45.76% | - | 4.25% | 11.78% | 54.24% |